Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in the NHS, and how you can get involved in suggesting future updates.
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.
Introducing the Medicines and Medical Devices Access Initiative (MMD): a new collaboration that aims to improve patient access to safe, clinically and cost-effective healthcare products.
Understand why we're prioritising key topic areas for evaluation and what it means for innovators
We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.
Dr Patterson, a GP working on the frontline of primary care, describes why he is encouraged by NICE's approval of tirzepatide (Mounjaro).
Page 1 of 10
Blog post listing page, 1 of 10